SciELO - Scientific Electronic Library Online

 
vol.32 número2Medicamentos de alto impacto económico y sanitario en la prestación farmacéutica hospitalariaPrograma de coordinación en la transición asistencial para la mejora de la farmacoterapia entre un Servicio de Urgencias y un Centro Sociosanitario índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Revista de la OFIL

versão On-line ISSN 1699-714Xversão impressa ISSN 1131-9429

Resumo

LLINARES-ESQUERDO, M et al. Pharmacokinetics monitoring of tumour necrosis factor inhibitors: utility in inflammatory bowel disease management. Rev. OFIL·ILAPHAR [online]. 2022, vol.32, n.2, pp.157-161.  Epub 13-Fev-2023. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x2022000200006.

Introduction:

The failure of biologic therapy in inflammatory bowel disease (IBD) is a common problem. The pharmacokinetic monitoring is a useful tool that allows to optimize these treatments.

Objective:

To describe the pharmacokinetic determinations of plasma concentrations of infliximab and adalimumab in patients with IBD and evaluate its impact on clinical decision.

Method:

Retrospective, observational study of two years duration (2017-2018) of the tumor necrosis factor (anti-TNF) inhibitor determinations performed in patients of the Digestive Service of a general hospital.

Results:

A total of 133 determinations were obtained about 66 subjects (38% adalimumab, 62% infliximab). The main reason (>55%) of the request for monitoring was the presence of active disease. More than half of the patients had concentrations outside the therapeutic range (51% of patients with adalimumab and 37% of those with infliximab had plasma levels below the lower range considered suboptimal). The maintenance of the previous dosage was recommended only in <40% of the monitoring and the degree of acceptance of the interventions were more than 80% in all cases. The analytical data of inflammation were reduced after monitoring without showing statistical significance in all cases.

Conclusion:

Standard anti-TNF regimen was not adequate to obtain range concentrations in more than half of analyzed cases. Monitoring has proven to be very useful in supporting clinical decision and it may promote an improvement in the clinical parameters of patients with IBD.

Palavras-chave : Inflammatory bowel diseases; drug monitoring; infliximab; adalimumab; monoclonal antibodies.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )